Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BXP.L Stock Summary
Top 10 Correlated ETFs
BXP.L
In the News
BXP.L Financial details
Company Rating
Buy
Market Cap
477.88M
Income
4.48B
Revenue
37.97B
Book val./share
95.65
Cash/share
2.21
Dividend
3.32
Dividend %
0.06%
Employees
5.5K
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
511.57
Forward P/E
-
PEG
-402.6
P/S
1.71
P/B
53.67
P/C
17.19
P/FCF
-21.83
Quick Ratio
0.07
Current Ratio
1.58
Debt / Equity
0.52
LT Debt / Equity
0.07
-
-
EPS (TTM)
10.03
EPS next Y
-
EPS next Q
-
EPS this Y
-0.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
15.1%
Revenue last 5Y
14.37%
Revenue Q/Q
-3.41%
EPS Q/Q
-23.1%
-
-
-
-
SMA20
-2.5%
SMA50
-4.88%
SMA100
-22%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
11%
ROC
0.12%
Gross Margin
44%
Oper. Margin
18%
Profit Margin
12%
Payout
35%
Shs Outstand
1.27B
Shs Float
297.32M
-
-
-
-
Target Price
-
52W Range
0.0-85.0
52W High
-
52W Low
-
RSI
35
Rel Volume
13.24
Avg Volume
20.78K
Volume
275K
Perf Week
-2.56%
Perf Month
-9.52%
Perf Quarter
-32.74%
Perf Half Y
-26.21%
-
-
-
-
Beta
0.743188
-
-
Volatility
0.49%, 1.74%
Prev Close
0%
Price
38
Change
-
BXP.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-06-30
Metric | History | 2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 39.69 | 51.15 | 57.44 | 66.11 | 77.71 | |
Net income per share | 5.68 | 6.8 | 7.88 | 11.49 | 11.48 | |
Operating cash flow per share | 4.07 | 0 | 0 | 0 | 0 | |
Free cash flow per share | -7.26 | -10.19 | -5.1 | -5.73 | -6.59 | |
Cash per share | 1.64 | 2.09 | 1.42 | 1.51 | 2.62 | |
Book value per share | 60.66 | 66.32 | 72.87 | 83.01 | 91.01 | |
Tangible book value per share | 57.17 | 62.73 | 69.46 | 79.44 | 88.32 | |
Share holders equity per share | 60.66 | 66.32 | 72.87 | 83.01 | 91.01 | |
Interest debt per share | 26.26 | 32.54 | 25.83 | 19.03 | 29.98 | |
Market cap | 22.45B | 16.23B | 14.88B | 44.06B | 34.79B | |
Enterprise value | 33.24B | 29.1B | 24.75B | 51.02B | 45.99B | |
P/E ratio | 8.85 | 5.35 | 4.23 | 8.59 | 6.79 | |
Price to sales ratio | 1.27 | 0.71 | 0.58 | 1.49 | 1 | |
POCF ratio | 12.34 | 0 | 0 | 0 | 0 | |
PFCF ratio | -6.93 | -3.57 | -6.54 | -17.22 | -11.83 | |
P/B Ratio | 0.83 | 0.55 | 0.46 | 1.19 | 0.86 | |
PTB ratio | 0.83 | 0.55 | 0.46 | 1.19 | 0.86 | |
EV to sales | 1.88 | 1.28 | 0.97 | 1.73 | 1.33 | |
Enterprise value over EBITDA | 7 | 5.85 | 4.37 | 7.05 | 5.98 | |
EV to operating cash flow | 18.27 | 0 | 0 | 0 | 0 | |
EV to free cash flow | -10.26 | -6.4 | -10.88 | -19.94 | -15.64 | |
Earnings yield | 0.11 | 0.19 | 0.24 | 0.12 | 0.15 | |
Free cash flow yield | -0.14 | -0.28 | -0.15 | -0.06 | -0.08 | |
Debt to equity | 0.61 | 0.65 | 0.53 | 0.4 | 0.53 | |
Debt to assets | 0.37 | 0.39 | 0.35 | 0.28 | 0.33 | |
Net debt to EBITDA | 2.27 | 2.59 | 1.74 | 0.96 | 1.46 | |
Current ratio | 1.26 | 1.04 | 1.15 | 1.47 | 1.45 | |
Interest coverage | 7.2 | 4.92 | 5.53 | 7.75 | 6.89 | |
Income quality | 0.72 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0.02 | 0.03 | 0.04 | 0.01 | 0.05 | |
Payout ratio | 0.2 | 0.17 | 0.17 | 0.11 | 0.32 | |
Sales general and administrative to revenue | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | |
Research and developement to revenue | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.08 | |
Capex to operating cash flow | -2.78 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.29 | -0.2 | -0.09 | -0.09 | -0.08 | |
Capex to depreciation | -5.98 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 88.06 | 100.73 | 113.68 | 146.52 | 153.35 | |
ROIC | 0.07 | 0.08 | 0.09 | 0.11 | 0.08 | |
Return on tangible assets | 0.06 | 0.06 | 0.07 | 0.1 | 0.08 | |
Graham Net | -28.66 | -33.83 | -29.88 | -23.1 | -33.13 | |
Working capital | 2.33B | 518.33M | 1.69B | 4.42B | 5.68B | |
Tangible asset value | 25.52B | 27.98B | 30.98B | 35.44B | 39.4B | |
Net current asset value | -5.04B | -6.09B | -4.27B | -1.11B | -3.09B | |
Invested capital | 0.41 | 0.46 | 0.32 | 0.21 | 0.3 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 503.94M | 856.57M | 1.28B | 1.71B | 2.22B | |
Average inventory | 4.91B | 6.19B | 6.69B | 7.26B | 9.46B | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 24.05 | 32.67 | 38.94 | 46.07 | 47.72 | |
Days of inventory on hand | 221.49 | 199.02 | 178.88 | 182.96 | 215.34 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 15.18 | 11.17 | 9.37 | 7.92 | 7.65 | |
Inventory turnover | 1.65 | 1.83 | 2.04 | 1.99 | 1.69 | |
ROE | 0.09 | 0.1 | 0.11 | 0.14 | 0.13 | |
Capex per share | -11.33 | -10.19 | -5.1 | -5.73 | -6.59 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q3
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 20.08 | 19.59 | 21.94 | 22.17 | 21.42 | |
Net income per share | 2.47 | 1.89 | 3.24 | 2.77 | 2.13 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | -0.39 | -2.47 | -1.53 | -1.56 | -1.12 | |
Cash per share | 1.32 | 2.62 | 1.96 | 2.79 | 2.21 | |
Book value per share | 89.13 | 91.01 | 94.25 | 93.52 | 95.65 | |
Tangible book value per share | 86.66 | 88.32 | 91.73 | 91.03 | 93.05 | |
Share holders equity per share | 89.13 | 91.01 | 94.25 | 93.52 | 95.65 | |
Interest debt per share | 27.14 | 28.38 | 27.62 | 26.53 | 26.25 | |
Market cap | 49.2B | 34.79B | 34.39B | 30.42B | 22.08B | |
Enterprise value | 60.44B | 45.99B | 45.53B | 40.67B | 32.48B | |
P/E ratio | 11.16 | 10.32 | 5.94 | 6.15 | 5.81 | |
Price to sales ratio | 5.49 | 3.98 | 3.51 | 3.08 | 2.31 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | -284.37 | -31.57 | -50.39 | -43.84 | -44.06 | |
P/B Ratio | 1.24 | 0.86 | 0.82 | 0.73 | 0.52 | |
PTB ratio | 1.24 | 0.86 | 0.82 | 0.73 | 0.52 | |
EV to sales | 6.75 | 5.26 | 4.65 | 4.11 | 3.4 | |
Enterprise value over EBITDA | 32.26 | 35.52 | 20.76 | 20.45 | 20.99 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | -349.33 | -41.73 | -66.71 | -58.62 | -64.83 | |
Earnings yield | 0.02 | 0.02 | 0.04 | 0.04 | 0.04 | |
Free cash flow yield | 0 | -0.03 | -0.02 | -0.02 | -0.02 | |
Debt to equity | 0.54 | 0.53 | 0.51 | 0.57 | 0.52 | |
Debt to assets | 0.33 | 0.33 | 0.32 | 0.34 | 0.32 | |
Net debt to EBITDA | 6 | 8.65 | 5.08 | 5.16 | 6.72 | |
Current ratio | 1.43 | 1.45 | 1.59 | 1.47 | 1.58 | |
Interest coverage | 6.43 | 4.05 | 6.79 | 5.92 | 4.77 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0.03 | 0 | 0 | 0 | 0.07 | |
Payout ratio | 1.4 | 0.01 | 0 | 0 | 1.63 | |
Sales general and administrative to revenue | 0.04 | 0.11 | 0.03 | 0.03 | 0.04 | |
Research and developement to revenue | 0 | 0.01 | 0 | 0 | 0 | |
Intangibles to total assets | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.02 | -0.13 | -0.07 | -0.07 | -0.05 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 70.4 | 62.19 | 82.94 | 76.39 | 67.72 | |
ROIC | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | |
Return on tangible assets | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | |
Graham Net | -27.59 | -28.15 | -26.64 | -29.47 | -32.64 | |
Working capital | 5.38B | 5.68B | 7.32B | 6.85B | 7.62B | |
Tangible asset value | 38.66B | 39.4B | 40.92B | 40.61B | 41.51B | |
Net current asset value | -3.46B | -3.09B | -1.8B | -2.32B | -1.36B | |
Invested capital | 0.3 | 0.3 | 0.29 | 0.28 | 0.27 | |
Average receivables | 3.86B | 3.55B | 3.11B | 3.27B | 1.65B | |
Average payables | 3.15B | 2.69B | 2.5B | 2.91B | 3.38B | |
Average inventory | 10.36B | 10.87B | 11.8B | 12.96B | 13.39B | |
Days sales outstanding | 41.52 | 30.51 | 29.86 | 30.02 | 0 | |
Days payables outstanding | 53.51 | 43.11 | 42.64 | 54.2 | 58.46 | |
Days of inventory on hand | 194.74 | 194.56 | 209.31 | 221.95 | 224.91 | |
Receivables turnover | 2.17 | 2.95 | 3.01 | 3 | 0 | |
Payables turnover | 1.68 | 2.09 | 2.11 | 1.66 | 1.54 | |
Inventory turnover | 0.46 | 0.46 | 0.43 | 0.41 | 0.4 | |
ROE | 0.03 | 0.02 | 0.03 | 0.03 | 0.02 | |
Capex per share | -0.39 | -2.47 | -1.53 | -1.56 | -1.12 |
BXP.L Frequently Asked Questions
What is Beximco Pharmaceuticals Limited stock symbol ?
Beximco Pharmaceuticals Limited is a BD stock and trading under the symbol BXP.L
What is Beximco Pharmaceuticals Limited stock quote today ?
Beximco Pharmaceuticals Limited stock price is $38 today.
Is Beximco Pharmaceuticals Limited stock public?
Yes, Beximco Pharmaceuticals Limited is a publicly traded company.